Literature DB >> 3593901

Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses.

B Edgar, C G Regårdh, P Lundborg, S Romare, G Nyberg, O Rönn.   

Abstract

The objective of this single-dose study was to evaluate the pharmacokinetics and haemodynamic changes in healthy male subjects following the administration of three oral (5, 15, and 40 mg) and two intravenous (1 and 3 mg) doses of felodipine, a new calcium antagonist with a selective effect on the peripheral resistance vessels. Felodipine was rapidly absorbed within 1 h when administered as an oral solution, but underwent extensive presystemic elimination. The systemic availability varied between 10 and 23 per cent. The disposition was adequately described by a two-compartment model: the disposition was essentially dose-independent up to 40 mg orally and 3 mg intravenously. Felodipine produced significant dose-dependent reduction of diastolic blood pressure and a significant reflexogenic increase in heart rate, without having any major effect on systolic blood pressure. These changes indicate that felodipine acts predominantly as an arteriodilator. The decrease in diastolic blood pressure and increase in heart rate were closely correlated with the plasma concentrations of unchanged felodipine, being maximal at 0.5 h and lasting for at least 4 h after the highest dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3593901     DOI: 10.1002/bdd.2510080305

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  20 in total

1.  A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.

Authors:  A D Bainbridge; R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.

Authors:  E Blychert; K Wingstrand; B Edgar; K Lidman
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Pharmacokinetics and haemodynamics of felodipine as monotherapy in hypertensive patients.

Authors:  B Edgar; P Collste; K Haglund; C G Regårdh
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

7.  Oral availability of fluticasone propionate.

Authors:  P Andersson; R Brattsand; K Dahlström; S Edsbäcker
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

8.  Pharmacokinetics of felodipine in patients with impaired renal function.

Authors:  B Edgar; C G Regårdh; P O Attman; M Aurell; H Herlitz; G Johnsson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

Review 9.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

10.  Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets.

Authors:  B Abrahamsson; M Alpsten; M Hugosson; U E Jonsson; M Sundgren; A Svenheden; J Tölli
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.